Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am 2008 Dec;22(6):1099-124, vii
Date
11/18/2008Pubmed ID
19010262Pubmed Central ID
PMC2630967DOI
10.1016/j.hoc.2008.08.007Scopus ID
2-s2.0-55849150238 (requires institutional sign-in at Scopus site) 61 CitationsAbstract
Patients present with a differential baseline risk of cancer based on normal and expected variations in genes associated with cancer. The baseline risk of developing cancer is acted on throughout life as the genome of different cells interacts with the environment in the form of exposures (eg, toxins, infections). As genetic damage is incurred throughout a lifetime (directly to DNA sequences or to the epigenome), events are set in motion to progressively disrupt normal cellular pathways toward tumorigenesis. This article attempts to characterize broad categories of genetic aberrations and pathways in a manner that might be useful for the clinician to understand the risk of developing cancer, the pathways that are disrupted, and the potential for molecular-based diagnostics.
Author List
Stadler ME, Patel MR, Couch ME, Hayes DNAuthor
Michael Stadler MD Associate Dean, Chief Medical Officer, Associate P in the Medical College Physicians Administration department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Epigenesis, GeneticHead and Neck Neoplasms
Humans
Neoplasms, Squamous Cell
Risk Factors